Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
Annexon(ANNX) Newsfilter·2024-06-04 19:00Annexon(ANNX) Newsfilter·2024-06-04 19:00
R1Annexon(ANNX) Newsfilter·2024-06-04 19:00